1. The multi-kinase inhibitor CG-806 exerts anti-cancer activity against acute myeloid leukemia by co-targeting FLT3, BTK, and aurora kinases.
- Author
-
Yu, Guopan, Zhang, Weiguo, Basyal, Mahesh, Nishida, Yuki, Mizumo, Hideaki, Ly, Charlie, Zhang, Hongying, Rice, William G., and Andreeff, Michael
- Abstract
AbstractDespite the development of several Fms-like tyrosine kinase 3 (
FLT3 ) inhibitors that have improved outcomes in patients withFLT3 -mutant acute myeloid leukemia (AML), drug resistance is frequently observed, which may be associated with the activation of additional pro-survival pathways, such as those regulated by BTK, aurora kinases (AuroK), and potentially others, in addition to acquired tyrosine kinase domain (TKD) mutations ofFLT3 gene.FLT3 may not always be a driver mutation. We evaluated the anti-leukemia efficacy of the novel multi-kinase inhibitor CG-806, which targets FLT3 and other kinases, to circumvent drug resistance and targetFLT3 wild-type (WT) cells. The anti-leukemia activity of CG-806 was investigated by measuring apoptosis induction and analyzing the cell cycle using flow cytometryin vitro . CG-806 demonstrated superior anti-leukemia efficacy compared to commercially available FLT3 inhibitors, bothin vitro andin vivo , regardless ofFLT3 mutational status. The mechanism of action of CG-806 may involve its broad inhibitory profile against FLT3, BTK, and AuroK. InFLT3 mutant cells, CG-806 induced G1 phase blockage, whereas inFLT3 WT cells, it resulted in G2/M phase arrest. Targeting FLT3 and Bcl-2 and/or Mcl-1 simultaneously results in a synergistic pro-apoptotic effect inFLT3 mutant leukemia cells. The results of this study suggest that CG-806 is a promising multi-kinase inhibitor with anti-leukemic efficacy regardless ofFLT3 mutational status. A phase 1 clinical trial of CG-806 for the treatment of AML has been initiated (NCT04477291).Key pointsThe multi-kinase inhibitor CG-806 exerts superior anti-leukemic activity in AML, regardless of itsFLT3 status.CG-806 triggered G1 arrest inFLT3 mutated cells and G2/M arrest inFLT3 WT cells through the suppression of FLT3/BTK and aurora kinases.Concomitantly targeting FLT3 and Bcl-2 and/or Mcl-1 exerted synergistic pro-apoptotic effects on bothFLT3 WT and mutated AML cells.The multi-kinase inhibitor CG-806 exerts superior anti-leukemic activity in AML, regardless of itsFLT3 status.CG-806 triggered G1 arrest inFLT3 mutated cells and G2/M arrest inFLT3 WT cells through the suppression of FLT3/BTK and aurora kinases.Concomitantly targeting FLT3 and Bcl-2 and/or Mcl-1 exerted synergistic pro-apoptotic effects on bothFLT3 WT and mutated AML cells. [ABSTRACT FROM AUTHOR]- Published
- 2024
- Full Text
- View/download PDF